Mattia Galli/LinkedIn
Sep 11, 2025, 08:32
Rivaroxaban vs Apixaban in AFib and PAD – What the Data Say
Mattia Galli, Assistant Professor at Sapienza Università di Roma, Associate Editor of European Heart Journal, shared a post on X:
”Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease.”
Read more here.
Stay updated with Hemostasis Today.
-
Feb 20, 2026, 10:06Rémi Bonjean: The 1st VHHs Against Active Rap1 to Monitor Platelet Activation
-
Feb 20, 2026, 09:50Latifa Alhassan: HIV Is a Danger Looming For Our Unborn Children and For The Economy of Ghana
-
Feb 20, 2026, 09:35Gregory Makris: Factor XI Makes the Leap from OCEANIC Stroke to the ESO 2025 Update
-
Feb 20, 2026, 09:27Waseem Mujahed: Compartment Syndrome as the Initial Presentation of Postpartum Acquired Hemophilia
-
Feb 20, 2026, 09:21Piotr Czempik: Viscoelastic Testing Guiding Lumbar Puncture in Waldenström’s Macroglobulinemia
-
Feb 20, 2026, 09:14Edoxaban Versus Dalteparin in Cancer-Associated VTE – JTH
-
Feb 20, 2026, 09:04Rens De Groot: The 1st Reported Case of Caplacizumab Resistance
-
Feb 20, 2026, 08:58Adeniji Mustapha: Advocacy for Health Doesn’t Require a License
-
Feb 20, 2026, 08:48Ahmed Nasreldein: Discussing the Inequities of Stroke Care in LMICs at ISC26